Protein‑Losing Enteropathy (PLE)

I. Introduction

• Definition: Excessive loss of plasma proteins into the gastrointestinal (GI) tract leading to hypoproteinemia and hypogammaglobulinemia; PLE is a syndrome, not a single disease.
• Major mechanisms:
  • Abnormal intestinal protein leakage across damaged mucosa or increased vascular/lymphatic permeability
  • Decreased return/uptake of protein via intestinal lymphatics (lymphatic obstruction, dilatation, or abnormal flow)
• Clinical context: Occurs as a manifestation of primary GI disorders or as a complication of systemic/extraintestinal diseases (see Causes, Table 1).

II. Pathophysiology (mechanistic summary)

PLE results from one or more overlapping processes that lead to non‑selective loss of plasma proteins (albumin, immunoglobulins, coagulation factors) into the gut lumen.

Key mechanisms

• Mucosal disruption/ulceration (e.g., inflammatory bowel disease, Crohn disease, Ménétrier disease, severe infections) → direct escape of plasma proteins into lumen.
• Loss/alteration of endothelial glycocalyx and proteoglycans (congenital disorders of glycosylation [CDG], sepsis) → increased capillary permeability and protein leakage.
• Raised hydrostatic pressures (e.g., elevated central venous pressure after Fontan palliation, right heart failure) → transudation of protein‑rich fluid into intestinal interstitium and lumen.
• Lymphatic hypertension or obstruction (primary intestinal lymphangiectasia, congenital lymphatic disorders, malignancy, thoracic duct obstruction) → rupture/dilation of lacteals with leakage of lymph into gut lumen.
• Tight junction and epithelial barrier dysfunction (celiac disease, inflammatory cytokine–mediated disruption) → increased paracellular flux of plasma proteins.
• Loss or dysfunction of epithelial glycosaminoglycans (GAGs) (CDG Ib/Ic, IBD) → amplified permeability to proteins.

III. Causes (comprehensive list)

Etiologies should be grouped for diagnostic approach: lymphatic disorders, mucosal diseases, hemodynamic causes, and systemic/genetic syndromes.

A. Lymphatic / primary intestinal lymphangiectasia and lymphatic malformations

• Primary intestinal lymphangiectasia (Waldmann disease)
• Hennekam lymphangiectasia‑lymphedema syndrome (OMIM 235510)
• Central conducting lymphatic anomaly (CCLA), lymphangiomatosis, generalised lymphatic anomaly, Kaposiform lymphatic anomaly
• Congenital lymphatic syndromes (Noonan, Gorham‑Stout disease in severe cases)
• Mutations associated with lymphatic dysfunction (e.g., plasmalemma‑vesicle‑associated protein mutations)

B. Cardiovascular / hemodynamic

• Fontan physiology–associated PLE
• Right heart failure, constrictive pericarditis, elevated venous pressure
• Thoracic duct obstruction (postoperative, tumor)

C. Mucosal inflammatory or erosive diseases

• Inflammatory bowel disease (Crohn disease > ulcerative colitis with severe small bowel disease)
• Celiac disease, chronic infections (Giardia, CMV, Cryptosporidium), Ménétrier disease
• NSAID enteropathy, peptic ulceration with severe erosions

D. Neoplastic and infiltrative

• Lymphoma, leukemic infiltration, intestinal tumors, lymphangioma, Kaposi sarcoma, metastatic melanoma

E. Congenital metabolic / genetic / syndromic causes

• Congenital disorders of glycosylation (CDG‑Ib, CDG‑Ic) — PLE can result from defective glycocalyx/proteoglycan biology
• DGAT1 deficiency, Urioste syndrome, macrocephaly‑cutis marmorata telangiectatica congenita variant, aplasia cutis congenita, autoimmune polyglandular syndrome type 1
• Infantile systemic hyalinosis, junctional epidermolysis bullosa

F. Post‑transplant, infectious, autoimmune and miscellaneous

• Posttransplant lymphoproliferative disease
• Cytomegalovirus enteritis (with or without Ménétrier disease)
• Systemic lupus erythematosus (rare; evaluate for renal losses)
• Langerhans cell histiocytosis, severe malnutrition, and other rare causes

IV. Clinical features

• Most common: peripheral edema (may progress to anasarca), abdominal distension/ascites
• Diarrhea, steatorrhea, failure to thrive, abdominal pain; symptoms vary with etiology and age
• Recurrent infections due to hypogammaglobulinemia and lymphopenia
• Effusions: pleural and pericardial effusions can occur with severe hypoalbuminemia
• Bleeding or prolonged PT/INR from loss of vitamin K–dependent clotting factors and reduced vitamin K absorption
• Thrombotic risk: loss of antithrombin III and other anticoagulant proteins can paradoxically increase venous thrombosis risk
• Growth delay and developmental concerns in children with chronic malnutrition

V. Diagnostic evaluation

A. Laboratory studies

• Serum: low total protein and albumin, low transferrin, low immunoglobulins (IgG, IgA, IgM), low ceruloplasmin and fibrinogen in severe cases
• Complete blood count: lymphopenia (common with lymphangiectasia), anemia if iron or vitamin losses occur
• Coagulation studies: prolonged PT/INR if vitamin K deficiency present
• Assess hepatic synthetic function and urinalysis to exclude nephrotic syndrome or renal protein loss

B. Stool testing

• Fecal alpha‑1 antitrypsin (A1AT) — preferred screening test for GI protein loss; collect timed or 24–72 hour stool specimen or calculate stool A1AT clearance relative to serum A1AT
• Important caveat: A1AT is degraded by gastric acid so upper GI bleeding or gastric protein loss may reduce sensitivity; consider acid suppression or interpret in context of anatomy
• Fecal inflammatory markers (calprotectin, lactoferrin) to screen for underlying inflammatory bowel disease

C. Imaging and lymphatic studies

• Radionuclide scans using labeled albumin or labeled tracers can localize protein loss but are less specific than lymphatic imaging
• Cross‑sectional imaging: contrast‑enhanced CT or MRE to evaluate bowel wall disease, masses, lymphadenopathy, and ascites
• Dynamic contrast MR lymphangiography (DCMRL) — increasingly the diagnostic gold standard for identifying lymphatic leaks, aberrant lymphatic connections, and planning percutaneous lymphatic interventions
• Conventional lymphangiography and intranodal lymphangiography may be used for planning embolization

D. Endoscopy and biopsy

• Upper and lower endoscopy with multiple, directed biopsies (patchy disease common)
• Endoscopic appearance of lymphangiectasia: whitish mucosal papules, chyle‑filled villi, or dilated lacteals; fat meal prior to procedure may accentuate findings
• Capsule endoscopy and double‑balloon enteroscopy are useful for small‑bowel mucosal disease and localization

E. Genetic and specialized testing

• Genetic testing for syndromic causes (CDGs, DGAT1, Noonan‑related genes, etc.) when clinical suspicion exists
• Isoelectric focusing / mass spectrometry of transferrin for CDG screening

VI. Differential diagnosis

• Nephrotic syndrome (urinary protein loss) — check urinalysis and urine protein:creatinine
• Liver failure or decreased protein synthesis — assess hepatic function and nutrition
• Severe malnutrition alone
• Dermal protein losses (exfoliative dermatitis, epidermolysis bullosa)

VII. Management and treatment principles

Management is etiology‑directed, supportive, and includes nutritional, immunologic, interventional radiology, medical, and surgical approaches.

A. General and supportive care

• High‑protein diet to replace losses (protein targets individualized; often >1.5–2 g/kg/day in children when tolerated)
• Low‑fat diet with medium‑chain triglyceride (MCT) supplementation: MCTs are absorbed directly into portal circulation and bypass lymphatics
• Replace fat‑soluble vitamins (A, D, E, K) and monitor levels
• Correct electrolyte abnormalities, provide adequate calories for catch‑up growth
• Periodic albumin infusions may be required for symptomatic hypoalbuminemia (short‑term measure); consider risks of volume overload
• In patients with hypogammaglobulinemia and recurrent infections: consider IVIG replacement tailored to IgG levels and infection history
• Vaccination: ensure pneumococcal, influenza, and other age‑appropriate vaccines given immune status permits; consult immunology for live vaccine decisions

B. Targeted medical therapies

• Octreotide: Somatostatin analogue that decreases lymph flow; useful in refractory intestinal lymphangiectasia (parenteral; dosing individualized)
• Steroids / immunosuppression: May benefit inflammatory mucosal causes (e.g., severe IBD) or stabilize epithelium in select situations (short‑term use guided by underlying disease)
• Anticoagulation: Treat documented thrombotic events or when hypercoagulable state suspected because of antithrombin loss; balance bleeding risk if anticoagulants are lost in stool
• Antiplasmin agents (tranexamic acid or investigational antiplasmin agents): limited evidence; occasionally used in lymphangiectasia
• Mannose supplementation: Effective therapy for CDG‑Ib (0.1–0.15 g/kg QID) to correct glycosylation defect and PLE in that specific diagnosis
• mTOR inhibitors (sirolimus): Emerging evidence for certain complex lymphatic anomalies (use in specialist centers)

C. Interventional and surgical options

• Percutaneous lymphatic embolization/embolotherapy guided by DCMRL or intranodal lymphangiography — effective for focal lymphatic leaks and increasingly first‑line for anatomically suitable lesions
• Thoracic duct decompression or ligation, surgical resection of localized intestinal lymphangiectasia, mesenteric exploration for obstructing lesions when indicated
• For Fontan‑associated PLE: cardiac catheterization with fenestration, surgical correction of hemodynamic lesions, thoracic duct interventions, and in refractory cases heart transplantation

D. Etiology‑specific therapies

• Treat inflammatory bowel disease, celiac disease (gluten‑free diet), CMV or other infections with appropriate antimicrobials
• Oncologic therapy for malignancy; treat posttransplant lymphoproliferative disease per hematology/oncology
• Manage congenital syndromes per multidisciplinary genetic/lymphatic teams

VIII. Complications and prognosis

• Complications: recurrent infections, thrombosis, growth failure, malnutrition, effusions and respiratory compromise from pleural effusions, and bleeding from coagulopathy
• Prognosis depends on the underlying cause, extent of lymphatic involvement, and responsiveness to therapy — focal lymphatic leaks treated with embolization may have excellent outcomes; Fontan‑associated PLE carries significant morbidity and variable response to therapy
• Long‑term follow‑up should include growth monitoring, serial albumin and immunoglobulin measurements, bone health evaluation (vitamin D), and surveillance for infections and thrombosis

IX. Practical diagnostic algorithm (summary)

1. Confirm hypoproteinemia and exclude renal (urine protein:creatinine), hepatic synthetic failure, and dermal losses.
2. Measure fecal A1AT (timed or 24–72 hour) to document GI protein loss.
3. Assess for inflammatory markers (fecal calprotectin), infectious stool studies, and celiac serology as indicated.
4. Cross‑sectional imaging (MRE/CT) and endoscopy with multiple biopsies for mucosal disease.
5. If lymphatic cause suspected, perform DCMRL/intranodal lymphangiography to localize leaks and plan intervention.
6. Genetic testing if congenital syndromic features or early onset unexplained PLE.

X. Key practice points (takeaways)

• PLE is a syndrome; always seek the underlying cause because targeted therapy may be curative.
• Fecal A1AT remains the practical first‑line test to document GI protein loss.
• DCMRL and percutaneous lymphatic interventions have transformed diagnosis and management of lymphatic‑mediated PLE.
• Address nutritional deficits, immunodeficiency (consider IVIG), thrombotic risk, and growth in pediatric patients.
• Care of pediatric PLE is multidisciplinary: gastroenterology, cardiology (when applicable), interventional radiology, nutrition, immunology, genetics, and surgery.